Wall Street analysts expect AstraZeneca plc (NYSE:AZN) to announce earnings of $0.42 per share for the current quarter, Zacks reports. Zero analysts have issued estimates for AstraZeneca’s earnings. AstraZeneca posted earnings per share of $1.12 during the same quarter last year, which would indicate a negative year-over-year growth rate of 62.5%. The business is expected to report its next earnings results on Thursday, November 8th.
On average, analysts expect that AstraZeneca will report full year earnings of $1.65 per share for the current fiscal year, with EPS estimates ranging from $1.65 to $1.66. For the next financial year, analysts forecast that the firm will report earnings of $1.89 per share, with EPS estimates ranging from $1.86 to $1.90. Zacks’ EPS averages are an average based on a survey of research analysts that follow AstraZeneca.
AstraZeneca (NYSE:AZN) last released its earnings results on Thursday, July 26th. The company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.38. AstraZeneca had a net margin of 11.98% and a return on equity of 29.89%. The business had revenue of $5.16 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter last year, the company earned $0.87 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis.
Institutional investors and hedge funds have recently made changes to their positions in the business. Bessemer Group Inc. increased its holdings in shares of AstraZeneca by 64.3% in the second quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock valued at $163,000 after purchasing an additional 1,820 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of AstraZeneca in the second quarter valued at approximately $175,000. Tiverton Asset Management LLC acquired a new stake in shares of AstraZeneca in the second quarter valued at approximately $178,000. Whittier Trust Co. boosted its stake in AstraZeneca by 420.0% in the first quarter. Whittier Trust Co. now owns 5,200 shares of the company’s stock valued at $182,000 after acquiring an additional 4,200 shares during the last quarter. Finally, Gilman Hill Asset Management LLC bought a new position in AstraZeneca in the second quarter valued at approximately $205,000. Hedge funds and other institutional investors own 15.63% of the company’s stock.
Shares of AstraZeneca traded down $0.23, hitting $39.38, during mid-day trading on Friday, according to MarketBeat.com. The company had a trading volume of 5,708,355 shares, compared to its average volume of 3,999,533. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.54 and a current ratio of 0.72. AstraZeneca has a 12 month low of $28.78 and a 12 month high of $39.76. The stock has a market cap of $100.33 billion, a PE ratio of 9.20, a PEG ratio of 2.16 and a beta of 0.61.
The firm also recently declared a semiannual dividend, which will be paid on Monday, September 10th. Shareholders of record on Friday, August 10th will be paid a dividend of $0.45 per share. This represents a yield of 2.35%. The ex-dividend date of this dividend is Thursday, August 9th. AstraZeneca’s dividend payout ratio is 20.56%.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Diversification For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.